PARP1 and breast carcinoma: Other reports have associated the upregulation of XRCC1 with increased risk of breast cancer; poor survival across low and high-risk breast cancer subtypes; increased tumor aggressiveness; and resistance to cisplatin, PARP inhibitors, and ionizing radiation [9,26,27,57].